Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2437-2445

  Parente Pereira, Ana C ^a   Whilding, Lynsey M ^b   Brewig, Nancy ^b   Van Der Stegen, Sjoukje J C ^a   Davies, David M ^a   Wilkie, Scott ^a   Van Schalkwyk, May C I ^a   Ghaem Maghami, Sadaf ^b   Maher, John ^a,c,d  

^a GUY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^d KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL EXPANSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; DRUG THERAPY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883315080     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301119     Document Type: Article

References (44)

1. Banerjee, S., and S. B. Kaye. 2013. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin. Cancer Res. 19: 961-968.
2. Ferlay, J., F. Bray, P. Pisani, and D. M. Parkin. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr. Accessed: July 15, 2013.
3. Siegel, R., D. Naishadham, and A. Jemal. 2012. Cancer statistics, 2012. CA Cancer J. Clin. 62: 10-29.
4. Siwak, D. R., M. Carey, B. T. Hennessy, C. T. Nguyen, M. J. McGahren Murray, L. Nolden, and G. B. Mills. 2010. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J. Oncol. 2010: 568938.
5. Anglesio, M. S., S. Kommoss, M. C. Tolcher, B. Clarke, L. Galletta, H. Porter, S. Damaraju, S. Fereday, B. J. Winterhoff, S. E. Kalloger, et al. 2013. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J. Pathol. 229: 111-120.
6. Ocana, A., F. Vera-Badillo, B. Seruga, A. Templeton, A. Pandiella, and E. Amir. 2013. HER3 overexpression and survival in solid tumors: a meta-analysis. J. Natl. Cancer Inst. 105: 266-273.
7. Paatero, I., H. Lassus, T. T. Junttila, M. Kaskinen, R. Butzow, and K. Elenius. 2013. CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol. Oncol. 129: 179-187.
8. Alper, O., E. S. Bergmann-Leitner, T. A. Bennett, N. F. Hacker, K. Stromberg, and W. G. Stetler-Stevenson. 2001. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J. Natl. Cancer Inst. 93: 1375-1384.
9. Alberti, C., P. Pinciroli, B. Valeri, R. Ferri, A. Ditto, K. Umezawa, M. Sensi, S. Canevari, and A. Tomassetti. 2012. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advancedstage epithelial ovarian cancer. Oncogene 31: 4139-4149.
10. Liebscher, C. A., J. Prinzler, B. V. Sinn, J. Budczies, C. Denkert, A. Noske, J. Sehouli, E. I. Braicu, M. Dietel, and S. Darb-Esfahani. 2013. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Hum. Pathol. DOI: 10.1016/j.humpath.2012.12.016.
11. Camilleri-Broet, S., A. C. Hardy-Bessard, A. Le Tourneau, D. Paraiso, O. Levrel, B. Leduc, S. Bain, H. Orfeuvre, J. Audouin, and E. Pujade-Lauraine; GINECO Group. 2004. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann. Oncol. 15: 104-112.
12. Tanner, B., D. Hasenclever, K. Stern, W. Schormann, M. Bezler, M. Hermes, M. Brulport, A. Bauer, I. B. Schiffer, S. Gebhard, et al. 2006. ErbB-3 predicts survival in ovarian cancer. J. Clin. Oncol. 24: 4317-4323.
13. Sheng, Q., and J. Liu. 2011. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br. J. Cancer 104: 1241-1245.
14. Makhija, S., L. C. Amler, D. Glenn, F. R. Ueland, M. A. Gold, D. S. Dizon, V. Paton, C. Y. Lin, T. Januario, K. Ng, et al. 2010. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J. Clin. Oncol. 28: 1215-1223.
15. Yarden, Y., and G. Pines. 2012. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12: 553-563.
16. Prasasya, R. D., K. Z. Vang, and P. K. Kreeger. 2012. A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib. Biotechnol. Bioeng. 109: 213-224.
17. Bast, R. C., Jr., L. Pusztai, B. J. Kerns, J. A. MacDonald, P. Jordan, L. Daly, C. M. Boyer, J. Mendelsohn, and A. Berchuck. 1998. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 17: 313-321.
18. Simpson, B. J., H. A. Phillips, A. M. Lessells, S. P. Langdon, and W. R. Miller. 1995. c-erbB growth-factor-receptor proteins in ovarian tumours. Int. J. Cancer 64: 202-206.
19. Scoccia, B., Y. M. Lee, C. Niederberger, and J. V. Ilekis. 1998. Expression of the ErbB family of receptors in ovarian cancer. J. Soc. Gynecol. Investig. 5: 161-165.
20. Sheng, Q., X. Liu, E. Fleming, K. Yuan, H. Piao, J. Chen, Z.Moustafa, R. K. Thomas, H. Greulich, A. Schinzel, et al. 2010. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17: 298-310.
21. Hsieh, S. S., C. Malerczyk, A. Aigner, and F. Czubayko. 2000. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int. J. Cancer 86: 644-651.
22. Sergina, N. V., M. Rausch, D. Wang, J. Blair, B. Hann, K. M. Shokat, and M. M. Moasser. 2007. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441.
23. Bianchi, S., D. Palli, M. Falchetti, C. Saieva, G. Masala, B. Mancini, R. Lupi, C. Noviello, J. Omerovic, M. Paglierani, et al. 2006. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J. Cell. Physiol. 206: 702-708.
24. Engelman, J. A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. M. Gale, X. Zhao, J. Christensen, et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
25. Karamouzis, M. V., F. A. Badra, and A. G. Papavassiliou. 2007. Breast cancer: the upgraded role of HER-3 and HER-4. Int. J. Biochem. Cell Biol. 39: 851-856.
26. Ritter, C. A., M. Perez-Torres, C. Rinehart, M. Guix, T. Dugger, J. A. Engelman, and C. L. Arteaga. 2007. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13: 4909-4919.
27. Zhou, B. B., M. Peyton, B. He, C. Liu, L. Girard, E. Caudler, Y. Lo, F. Baribaud, I. Mikami, N. Reguart, et al. 2006. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10: 39-50.
28. Fujiwara, S., Y. Terai, H. Kawaguchi, M. Takai, S. Yoo, Y. Tanaka, T. Tanaka, S. Tsunetoh, H. Sasaki, M. Kanemura, et al. 2012. GPR30 regulates the EGFRAkt cascade and predicts lower survival in patients with ovarian cancer. J. Ovarian Res. 5: 35.
29. Davies, D. M., J. Foster, S. J. Van Der Stegen, A. C. Parente-Pereira, L. Chiapero-Stanke, G. J. Delinassios, S. E. Burbridge, V. Kao, Z. Liu, L. Bosshard-Carter, et al. 2012. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol. Med. 18: 565-576.
30. Stortelers, C., M. L. van De Poll, A. E. Lenferink, M. M. Gadellaa, C. van Zoelen, and E. J. van Zoelen. 2002. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers. Biochemistry 41: 4292-4301.
31. Wilkie, S., S. E. Burbridge, L. Chiapero-Stanke, A. C. Pereira, S. Cleary, S. J. van der Stegen, J. F. Spicer, D. M. Davies, and J. Maher. 2010. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285: 25538-25544.
32. Welander, C. E., R. B. Natale, and J. L. Lewis, Jr. 1982. In vitro growth stimulation of human ovarian cancer cells by xenogeneic peritoneal macrophages. J. Natl. Cancer Inst. 69: 1039-1047.
33. Huang, S., M. Van Arsdall, S. Tedjarati, M. McCarty, W. Wu, R. Langley, and I. J. Fidler. 2002. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 94: 1134-1142.
34. Robinson-Smith, T. M., I. Isaacsohn, C. A. Mercer, M. Zhou, N. Van Rooijen, N. Husseinzadeh, M. M. McFarland-Mancini, and A. F. Drew. 2007. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 67: 5708-5716.
35. Maher, J., R. J. Brentjens, G. Gunset, I. Riviere, and M. Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 20: 70-75.
36. Riviere, I., K. Brose, and R. C. Mulligan. 1995. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92: 6733-6737.
37. Lockley, M., M. Fernandez, Y. Wang, N. F. Li, S. Conroy, N. Lemoine, and I. McNeish. 2006. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res. 66: 989-998.
38. Jandial, D. D., K. Messer, S. Farshchi-Heydari, M. Pu, and S. B. Howell. 2009. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol. Oncol. 115: 362-366.
39. Grupp, S. A., M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. T. Teachey, A. Chew, B. Hauck, J. F. Wright, et al. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368: 1509-1518.
40. Parente-Pereira, A. C., J. Burnet, D. Ellison, J. Foster, D. M. Davies, S. van der Stegen, S. Burbridge, L. Chiapero-Stanke, S. Wilkie, S. Mather, and J. Maher. 2011. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 31: 710-718.
41. Mistry, P., L. R. Kelland, G. Abel, S. Sidhar, and K. R. Harrap. 1991. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer 64: 215-220.
42. Palma, J. P., S. K. Aggarwal, and A. Jiwa. 1992. Murine macrophage activation after cisplatin or carboplatin treatment. Anticancer Drugs 3: 665-676.
43. Chang, C. L., Y. T. Hsu, C. C. Wu, Y. Z. Lai, C. Wang, Y. C. Yang, T. C. Wu, and C. F. Hung. 2013. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res. 73: 119-127.
44. Spear, P., A. Barber, and C. Sentman. 2013. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology 2: e23564.